UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 18,434 Shares of Aehr Test Systems $AEHR

Key Points

• UBS Asset Management increased its Aehr Test Systems stake by 53.6% in the second quarter, purchasing 18,434 shares and bringing its holdings to 52,815 shares worth approximately $5.1 million.
• Institutional investors and hedge funds own 69.69% of AEHR, with BlackRock initiating a position worth about $255.5 million and Wellington Management increasing its stake by nearly 130%.
• AEHR shares recently traded at $90.79, while analysts maintained an overall “Buy” consensus with an average price target of $136.67; however, company insiders sold 109,475 shares worth $13.8 million during the latest quarter.

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Aehr Test Systems (NASDAQ:AEHR - Free Report) by 53.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 52,815 shares of the semiconductor company's stock after purchasing an additional 18,434 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.16% of Aehr Test Systems worth $5,073,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the company. BlackRock Inc. bought a new position in Aehr Test Systems during the second quarter worth about $255,476,000. Vanguard Group Inc. raised its stake in Aehr Test Systems by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 2,337,433 shares of the semiconductor company's stock valued at $47,193,000 after buying an additional 49,243 shares during the period. Wellington Management Group LLP lifted its position in shares of Aehr Test Systems by 129.9% in the fourth quarter. Wellington Management Group LLP now owns 830,664 shares of the semiconductor company's stock valued at $16,771,000 after buying an additional 469,400 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Aehr Test Systems by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 685,694 shares of the semiconductor company's stock valued at $13,846,000 after buying an additional 5,591 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Aehr Test Systems during the 2nd quarter worth approximately $64,433,000. 69.69% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Aehr Test Systems

In other news, COO Adil Engineer sold 15,000 shares of the business's stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $131.02, for a total value of $1,965,300.00. Following the completion of the transaction, the chief operating officer directly owned 46,977 shares in the company, valued at approximately $6,154,926.54. The trade was a 24.20% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Rhea J. Posedel sold 5,973 shares of the company's stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $140.00, for a total transaction of $836,220.00. Following the sale, the director directly owned 381,989 shares of the company's stock, valued at approximately $53,478,460. This trade represents a 1.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 109,475 shares of company stock worth $13,827,160 in the last quarter. 6.80% of the stock is currently owned by corporate insiders.

Aehr Test Systems Trading Up 5.3%

Shares of AEHR stock opened at $90.79 on Wednesday. The stock has a market cap of $2.96 billion, a P/E ratio of -378.28 and a beta of 3.06. Aehr Test Systems has a 1 year low of $18.70 and a 1 year high of $147.40. The stock has a 50 day simple moving average of $90.11 and a 200 day simple moving average of $79.85.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on AEHR. Jefferies Financial Group started coverage on Aehr Test Systems in a report on Thursday, August 13th. They set a "buy" rating and a $175.00 target price on the stock. Lake Street Capital reaffirmed a "buy" rating and set a $110.00 price objective on shares of Aehr Test Systems in a research report on Wednesday, July 15th. Zacks Research upgraded shares of Aehr Test Systems from a "hold" rating to a "strong-buy" rating in a report on Friday, July 17th. Freedom Capital raised shares of Aehr Test Systems from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 16th. Finally, Weiss Ratings cut shares of Aehr Test Systems from a "sell (d)" rating to a "sell (e+)" rating in a research note on Wednesday, July 29th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Aehr Test Systems presently has an average rating of "Buy" and a consensus price target of $136.67.

Aehr Test Systems Company Profile

Aehr Test Systems develops, manufactures and sells semiconductor test and burn-in equipment used by device manufacturers to ensure quality and reliability of integrated circuits. Its products are designed for wafer-level reliability assessment, functional test and stress screening of memory devices, system-on-chips, optical components and power semiconductors. By focusing on wafer-level burn-in and testing processes, the company helps reduce cost and improve yield for high-volume semiconductor production.

The company's product portfolio includes FOX series wafer probe test and burn-in systems as well as ABTS burn-in ovens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.